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Background: Recurrent fetal loss (RPL) is one of the most common cause of sterility. Several 
studies identiﬁ  ed thrombophilia as the principal cause of recurrent pregnancy loss. However, 
reported studies often do not evaluate other causes of miscarriages in their inclusion and exclusion 
criteria. So the aim of our study was to investigate the role of inherited thrombophilia in patients 
with RPL and without other causes of RPL.
Patients and methods: Patients with 2 or more ﬁ  rst trimester abortion or with 1 or more 
late pregnancy loss were considered for this study. In order to evaluate the causes of RPL we 
looked for chromosomal, endocrine, chronic inﬂ  ammatory, and infectious alterations. 90 patients 
affected by unexplained RPL were enrolled and tested for hemostatic alterations. These women 
were tested for inherited and/or acquired thrombophilia by MTHFR C677T gene polymorphism, 
factor V Leiden gene polymorphism, PTHRA20210G gene polymorphism, protein S deﬁ  ciency, 
protein C deﬁ  ciency, antithrombin III deﬁ  ciency, lupus anticoagulant, and anticardiolipin 
antibodies Ig G and Ig M.
Results: Acquired and/or inherited thrombophilia are strongly associated with RPL when other 
common causes of miscarriage were excluded. 78% of tested women showed hemostatic abnormali-
ties. Several women with combined thrombophilic defects were also identiﬁ  ed by our data.
Conclusion: After a thorough evaluation of other causes of miscarriage women affected by 
RPL should be tested for thrombophilia. Our data demonstrated 78% of women with one or 
combined thrombophilic conditions. Differences with previous studies should be related to 
difference in the inclusion and exclusion criteria and ethnic background. Because these patients 
often also show a hypercoagulable state, it an antithrombotic treatment before and during 
pregnancy may improve their clinical outcome (ie, secondary prevention of miscarriage and 
primary thromboprophylaxis).
Keywords: recurrent pregnancy loss, late pregnancy loss, thrombophilia, hypercoagulable state, 
hyperhomocysteinemia, factor V Leiden, prothrombin, antithrombotic drugs
Background
Recurrent fetal loss (RPL) is one of the most common causes of sterility. In a recent 
study we underlined the relevant role of d-dimer, as a marker of hypercoagulable 
state, in identifying thrombophilia in women affected by primary or secondary sterility 
(Di Micco et al 2004).
In 1999 Brenner et al (1999) identiﬁ  ed thrombophilia as a principal cause in more 
than 40% of women affected by RPL. Further studies underlined a pathogenetic role 
of inherited thrombophilia in women affected by RFL. Sanson et al (1996) reported 
an increased frequency of antithrombin III, protein C, and protein S deﬁ  ciency in Biologics: Targets & Therapy 2008:2(4) 898
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women with RPL, while several studies underlined the 
role of inherited thrombophilia (in particular related to 
factor V Leiden gene polymorphism and prothrombin 
A20210G gene polymorphism) in the pathophysiology 
of recurrent pregnacy loss (Brenner et al 1999; Carp et al 
2002; Finan et al 2002; Grandone et al 1997; Greer 2003; 
Martinelli et al 2000; Pabinger et al 2000; Pickering et al 
2001; Pihusch et al 2001; Rai et al 2001; Reznikoff-Etievan 
et al 2001; Younis et al 2001).
Yet increasing evidence is available on the relation-
ship between hyperhomocysteinemia and methylene-
tetra-hydro-folate reductase (MTHFR) C677T gene 
polymorphism and unexplained recurrent pregnancy loss. 
Several reports have described an association between early 
recurrent pregnancy loss and hyperhomocysteinemia and/or 
MTHFR C677T gene polymorphism (Fatini et al 2000; 
Lissak et al 1999; Nelen et al 1997; Wouters et al 1993).
Acquired thrombophilia has also been associated with 
RPL. Dossenbach-Glaninger et al (2004) revealed that 
elevated maternal plasma levels of clotting factor VIII tend 
to be associated with an increased risk of RPL. Several 
studies have shown an association between RPL and 
primary or secondary antiphospholipid syndrome (Asherson 
and Cervera 1994; Chakrabarti et al 1999; Das et al 1991; 
Higashino et al 1998; Infante-Rivard et al 1991; Noble et al 
2005). On this topic, a rare condition, acquired deﬁ  ciency of 
clotting factor XII, has been described which Braulke et al 
(1993) identiﬁ  ed for the ﬁ  rst time a factor XII deﬁ  ciency 
in RPL. Subsequently, Jones et al (2001) reported acquired 
factor XII deﬁ  ciency in a subpopulation of women with 
antiphospholipid antibodies and RPL. Acquired clotting 
inhibitors, such as antibodies directed toward clotting factors, 
may induce an acquired clotting factors deﬁ  ciency. In this 
ﬁ  eld, we recently identiﬁ  ed an unusual clinical presentation of 
antiphospholipid syndrome with clotting factor XII deﬁ  ciency 
and the presence of antibodies to factor XII in a young woman 
with unexplained recurrent RPL (D’Uva et al 2005).
However, reported studies often do not evaluate other 
causes of miscarriages in their inclusion and exclusion 
criteria. So the aim of our study was to investigate the role of 
inherited thrombophilia in patients with RPL after exclusion 
of other causes of RPL.
Patients and methods
Patients
Patient selection
Starting from 1 January 2005, we selected 250 outpatients 
women referred to our Sterility Center for infertility owing 
to RPL. All patients with 2 or more ﬁ  rst trimester abortions 
or with 1 or more late pregnancy loss were considered for 
this study. In order to evaluate the causes of RPL we looked 
for chromosomal alterations, endocrine diseases, chronic 
inﬂ  ammatory, and infectious diseases.
All patients underwent karyotype study in order to detect 
several chromosomal aberrations such as balanced translo-
cations. The uterine cavity was evaluated anatomically by 
transvaginal ultrasound scan and hysterosalpingography 
and/or hysteroscopy in order to detect mullerian malforma-
tions or the presence of ﬁ  broids or polyps. Endocrinological 
assessment included screening for diabetes, hypothyroidism, 
hypopituitarism, hyperprolactinemia, luteal insufﬁ  ciency, and 
polycystic ovarian syndrome (PCOS). Basal FSH, LH, and 
estradiol, and luteal phase progesterone, TSH, prolactin levels, 
and fasting glucose were evaluated in all patients. In addition, 
trans-vaginal USG and androgens levels were assessed to look 
for PCOS. Chronic inﬂ  ammation owing to immunological 
disease such as erythematosus lupus, rheumatoid arthritis, 
and systemic sclerosis were also studied. Serum level of 
antinuclear antibodies (ANA), antimithocondrial antibodies 
(AMA), and smooth muscle cells antibodies (SMA), rheuma-
toid arthritis, and levels of C reactive protein were assessed. 
Infective disease owing to Chlamydia spp, was evaluated by 
speciﬁ  c Chlamydia assays, associated with serological levels 
of speciﬁ  c IgG and IgM against Chlamydia spp. Moreover 
patients affected by obesity were excluded, in particular 
women with body mass index  27 were not enrolled in the 
study. Table 1 summarizes exclusion criteria.
Patient group
After this screening we selected 115 patients affected by 
unexplained RPL. These women were tested for inherited 
and/or acquired thrombophilia by methylene-tetra-hydrofolate 
Table 1 Inclusion and exclusion criteria of selected subjects
Inclusion criteria Exclusion criteria
2 or more ﬁ  rst trimester abortion Hypopituitarism
1 or more late pregnancy loss Hypothyroidism
Normal karyotype Hyperprolactinemia
Normal uterine cavity Luteal insufﬁ  ciency
Tubal patency PCOS
Inﬂ  ammatory or infectious disease
Diabetes
Obesity
Single abortion
Abbreviation: PCOS, polycystic ovarian syndrome.Biologics: Targets & Therapy 2008:2(4) 899
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reductase (MTHFR) C677T gene polymorphism, factor V 
Leiden gene polymorphism, PTHRA20210G gene polymor-
phism, protein S deﬁ  ciency, protein C deﬁ  ciency, antithrombin 
III deﬁ  ciency, lupus anticoagulant, and anticardiolipin antibod-
ies Ig G and Ig M.
Methods
Whole blood samples were collected from all selected 
subjects in the study by venipuncture from antecubital vein 
in order to screen for possible involvement hemostasis 
alteration.
First blood sample
A whole blood sample (5 mL) was collected in EDTA by 
venipuncture of antecubital vein. DNA was extracted using 
the “NUCLEON BACC” kit (Amershan, Germany). Patients 
were screened for the following mutations: Factor V G1691A 
gene polymorphism, A20210G gene polymorphism of the 
prothrombin, and C677T gene polymorphism of MTHFR 
using PCR ampliﬁ  cation with speciﬁ  c primers and the Light 
Cycler apparatus (Roche, Italy).
Second blood sample
A second blood sample (5 mL) was collected in a Vacutainer 
tube containing 0.129 M sodium citrate; the ratio of 
anticoagulant to blood was 1/9 v/v.
Plasma activity of antithrombin III and protein S were 
evaluated with commercial kits (Bhoeringer, Germany) as 
was plasma protein S activity (Biopool, Sweden).
Anticardiolipin antibodies Ig G and IgM were detected 
by an ELISA method (anticariolipine Bouty, Italy).
Lupus anticoagulant assays were performed using 
a DRVVT kit (Screen and Conﬁ  rm, Gradipore, North 
Ryde, Australia) and according to the recommenda-
tions of the International Society of Thrombosis and 
Haemostasis.
Control group
Seventy-ﬁ  ve healthy age-matched subjects were enrolled 
as a control group. We included patients with one or more 
successful pregnancy and without gestational complica-
tion (intrauterine growth restriction, stillbirth, and abruptio 
placentae) or any abortion. We excluded patients with 
previous arterial and/or venous thrombosis. We also excluded 
subjects with ﬁ  rst degree parents affected by arterial and/or 
venous thrombosis before than 65 years old.
Statistical analysis
Statistical analysis was based on Pearson chi-square (Npar 
tests); differences were considered to be significant if 
p  0.05.
Results
The characteristics of study and control groups are 
summarised in Table 2. Patients were well matched according 
to age. Ninety patients showed alteration of hemostasis 
with a trend toward thrombophilia. Eighty-three patients 
with 2 or more early pregnancy losses and 7 patients with 
1 or more late pregnancy loss were enrolled. Patients with 
RPL showed more gestations (median 3.1 vs 1.7 of control 
group), although only 10% ended with delivery of a living 
neonate.
Thrombophilia was present in 90/115 patients (78%) of 
study group compared with 12/75 (16%) of control subjects 
(p  0.001, signiﬁ  cant, s). Eighty-four patients showed 
isolated hemostatic abnormalities with a trend toward hyper-
coagulable state, while 6 patents showed combined defects 
inducing a hypercoagulable state, too.
The evaluation of the analyzed thrombophilic condi-
tions revealed that factor V Leiden heterozygosity was 
present in 6/115 (5.2%) patients with RPL vs 1/75 (1.3%) 
subjects of control group (p 0.091, ns); factor V Leiden 
homozygosity was absent in both study and control groups 
Table 2 Frequency of thrombophilic alterations in women with RPL without other causes of miscarriage and control group
Study group (115 patients) Control group (75 patients) p
MTHFR C677T homozigosity 35/115 (30.0%) 7/75 (9.3%) 0.001, s
FVL heterozigosity 6/115 (5.2%) 1/75 (1.3%) 0.09, ns
PTHRA20210G heterozigosity 18/115 (15%) 2/75 (2.6%) 0.001, s
PS deﬁ  ciency 15/115 (13%) 2/75 (2.6%) 0.003, s
PC deﬁ  ciency 2/115 (1.7%) 0/75 (0%) 0.194, ns
APS 10/115 (8.6%) 0/75 (0%) 0.003, s
Combined defects 6/115 (5.2%) 0/75 (0%) 0.003, s
Abbreviations: RPL, recurrent pregnangy loss; MTHFR C677T, methylene tetrahydro folate reductase gene polymorphism; FVL, factor V Leiden gene polymorphism; PTHR 
A20210G, prothrombin gene polymorphism; PS, protein S deﬁ  ciency; PC, protein C deﬁ  ciency; APS, antiphospholipid syndrome.Biologics: Targets & Therapy 2008:2(4) 900
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(statistical analysis not performed) (data not shown in 
Table 2). Prothrombin A20210G heterozygosity was present 
in 18/115 (15%) patients with RPL vs 2/75 (2.6%) control 
(p 0.001, s), while prothrombin A20210G homozigosity was 
absent both in study and control groups (statistical analysis 
not performed) (data not shown in Table 2). MTHFR C677T 
homozygosity was present in 35/115 (30.0%) patients with 
RPL vs 7/75 (9.3%) control (p: 0.001, s).
We did not ﬁ  nd any subjects with antithrombin III deﬁ  -
ciency in either group (statistical analysis not performed) 
(data not shown in Table 2). Yet 2/115 (1.7%) patients with 
RPL showed protein C deﬁ  ciency vs no control subjects 
(p 0.194, ns). Protein S deﬁ  ciency was present in 15/115 
(13.0%) of patients with RPL vs 2/75 (2.6%) subjects of 
control subjects (p 0.003, s).
We also analyzed combined thrombophilic defects in 
our population. Of women affected by RPL, 6/115 (5.2%) 
showed combined thrombophilic defects compared with 
no control subjects (p 0.023, s). Analysis of combined 
thrombophilia underlined these combined defects: 2 sub-
jects showed protein S deﬁ  ciency associated with MTHFR 
C677T homozygosity, 2 subjects showed protein S 
deﬁ  ciency associated with prothrombin A20210G hetero-
zygosity, 1 subject showed MTHFR C677T homozygosity 
associated with prothrombin A20210G heterozygosity, and 
1 subject showed factor V Leiden heterozigosity associated 
with prothrombin A20210G heterozygosity.
Acquired thrombophilia owing to antiphospolipid 
syndrome was detected in 10/115 (8.6%) study group 
women compared with no control subjects (p 0.003, s). LAC 
was present alone in 4/115 (3.4%) study group subjects; 
anticardiolipin antibodies (ie, IgG and/or IgM) were present 
alone in 4/115 (3.4%) study group subjects. LAC and 
anticardiolipin antibodies were both present in 2/115 study 
group subjects (1.7%).
Discussion
Alteration of hemostasis with a trend toward thrombophilia 
has been frequently associated to RPL. Several published 
studies seem to differ not only on the frequency of speciﬁ  c 
alteration but also on the inclusion and exclusion criteria of 
enrolled patients. For this reason we may observe also great 
differences about the involvement of thrombophilia during 
the evaluation of patients with RPL (Robertson et al 2006). 
However, the incidence of thrombophilia seems to increase 
if any causes of miscarriage, such as endocrine alterations 
and uterine malformations, are also excluded from the study 
population (Sarig et al 2002). Our data conﬁ  rmed this trend 
and showed a strong association, reaching nearly 78%, of one 
or more thrombophilic defects in women with RPL if other 
common causes of miscarriage are excluded. Before evalu-
ating thrombophilia in our selected patients, we excluded 
several conditions associated with miscarriage such as uterine 
malformation, anovulation, tube patency, endocrine diseases 
(ie, diabetes, hypothyroidism, hypopituitarism, hyperpro-
lactinemia, luteal insufﬁ  ciency, and PCOS), chronic and/or 
infectious diseases, and karyotype alterations.
Our data are also of interest if the frequency of speciﬁ  c 
thrombophilic defects is analyzed. We did not ﬁ  nd a strong 
association with factor V Leiden gene polymorphism 
and RPL, while we did ﬁ  nd an increased frequency of 
prothrombin A20210G gene polymorphism compared with 
control subjects and also with other studies. Our data for 
prothrombin A20210G gene polymorphism was statisti-
cally signiﬁ  cant. However, these differences from previous 
studies may be linked also to ethnic background, according 
to published data on geographical distribution of these 
gene variants (Ioannou et al 2000; Rosendaal et al 1998; 
Sarig et al 2002; Zalavras et al 2003). This reason may 
also explain the strong impact of the homozygosity of the 
MTHFR C677T gene polymorphism, which is present in the 
homozygosity gene variants in nearly 30% of the enrolled 
patients. Although MTFHR C677T gene polymorphism is 
a well recognized thrombotic risk factor, in particular for 
venous thromboembolism, data on its role in the pathophysi-
ology of RPL per se is still a matter of discussion because 
of the role of folic acid in homocysteine metabolism. From 
another point of view, the relevant incidence of the MTHFR 
C677T gene variant may also be due to ethnic background, 
and for this reason we may also observe an increased inci-
dence of the TT genotype in the control group (ie, nearly 
16%) (Rozen 2001). However, from a metabolic point of 
view previous studies may underestimate the involvement 
of homocysteine metabolism and MTHFR C677T gene 
variants in RPL: usually MTHFR C677T gene variants are 
analyzed only if a thrombotic disease, such as RPL, is associ-
ated with hyperhomocysteinemia. Yet the role of folic acid 
fortiﬁ  cation during pregnancy is well known (Andersson 
et al 1992; Bonnette et al 1998) for preventing neural tube 
defects (Smithells et al 1980), and this folic acid fortiﬁ  cation 
may determine also a transient reduction in homocysteine 
levels during pregnancy.
We did not ﬁ  nd in our population homozygosity for 
prothrombin A20210G or factor V Leiden gene polymor-
phisms, or antithrombin deﬁ  ciency. However, we did ﬁ  nd 
a low incidence of protein C deﬁ  ciency in our population, Biologics: Targets & Therapy 2008:2(4) 901
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and these data seem to be in agreement with the results of 
Sarig et al (2002).
An increased frequency (statistically significant) of 
protein S deﬁ  ciency was also found in our population, 
highlighting again its relevance in these patients affected by 
RPL. These data are also in agreement with those previously 
reported (Sanson et al 1996; Sarig et al 2002).
We found also a statistically significant increased 
incidence of antiphospholipid syndrome in women with 
RPL compared with control, which agrees with published 
data (Sarig et al 2002).
Particular attention should also be paid to the incidence 
of combined defects in women with RPL, which reached 
nearly 10% of investigated women. This observation could 
be very interesting for future studies because previous case 
control studies have underlined a potential role of combined 
thrombophilic defects in women with late pregnancy loss 
(Gris et al 1999; Sotiriadis et al 2007). We observed that more 
than 60% of our patients showed not only late pregnancy 
loss, as already reported in the literature, but also early RPL. 
Because our data on the role of combined thrombophilic 
defects in women with RPL reach statistical signiﬁ  cance, 
even though the reduced number of selected patients was 
few, the role of combined thrombophilic defects in women 
with any type of recurrent pregnancy should be analyzed in 
further studies.
Our data emphasizes the role of thrombophilia in women 
with RPL. Speciﬁ  c research on the alteration of hemostasis 
in this clinical setting is particularly relevant in order to 
establish a possible protocol that supports clinical surveil-
lance and follow up associated with thromboprophylaxis of 
these patients, both for repeated pregnancy loss and deep 
venous thrombosis, which is still a common complication 
in pregnant women. For the frequency of thrombophilic 
defects, we conﬁ  rmed a major role for protein S deﬁ  ciency, 
antiphospholipid syndrome, prothrombin A20210G gene 
variants, and MTHFR C677T gene variants, which has been 
reported previously. Interestingly, our data differ from those 
previously published in terms a reduced frequency of factor 
V Leiden gene variant. However, this gene variant should 
be also considered in this clinical setting because it has been 
observed in several of our patients, although its frequency 
did not reach statistical signiﬁ  cance, probably because of a 
different ethnic distribution in our geographical area.
Alteration of hemostasis with a trend toward hyperco-
agulable state should be evaluated soon if patients affected 
by RPL do not show other causes of miscarriage. Because 
such patients may show an asymptomatic hyperocagulable 
state (Di Micco et al 2004) and because antithrombotic 
treatment in thrombophilic pregnant women with previous 
RPL has been shown to improve prognosis of related preg-
nancy (Brenner et al 2005a, b; Stephenson et al 2004), the 
possibility of starting early antithrombotic treatment (ie, 
before the beginning of pregnancy) should be studied, based 
on aspirin and/or low-molecular-weight heparin in order to 
evaluate further improvements in pregnancy outcome of 
thrombophilic women.
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